San Diego-based medical gadget firm ResMed has introduced the acquisition of mementor, a client software program developer that provides a digital answer for insomnia.
The monetary phrases of the transaction weren’t disclosed.
The acquisition of Leipzig, Germany-based mementor lays the muse for ResMed to construct its digital sleep medication portfolio in Germany, the corporate stated. The deal was accomplished on Aug. 1.
Mementor shall be built-in into ResMed in Germany as a separate enterprise section and can function a platform for additional developments within the discipline of digital well being. By the acquisition, mementor can leverage ResMed Germany’s broader community to extend adoption of its digital well being utility, somnio.
The enterprise section shall be co-led by mementor co-founder and CEO Dr. Noah Lorenz and Katherina Jekerle, who was beforehand ResMed Germany’s senior advertising director and a member of the German management crew.
WHY THIS MATTERS
Mementor developed the digital well being utility somnio, which focuses on enhancing sleep in sufferers with identified insomnia. Somnio fills a care hole by offering a substitute for prevailing drug remedy.
ResMed stated somnio enhances its efforts to extend consciousness of insomnia and sleep apnea and provides entry to efficient house therapies.
Somnio is out there in Germany through “app on prescription.”
Somnio is Germany’s first and solely completely authorized digital well being utility within the discipline of sleep medication, in line with ResMed. This makes it eligible for reimbursement in Germany.
The medical effectiveness of somnio has been demonstrated in two randomized managed trials, displaying a sustained enchancment in customers’ sleep after two and 12 months, in line with ResMed.
THE LARGER TREND
Based in Switzerland in 2014 by Dr. Noah Lorenz, Alexander Rötger, Jan Kühni and Daniel Rotzetter, mementor developed and owns the digital insomnia remedy answer somnio.
It’s Germany’s first and solely completely authorized Digital Well being Software (DiGA) within the discipline of sleep medication and can be compliant with the European Union’s information safety necessities beneath the Normal Information Safety Regulation.
In Germany, roughly 1 in 10 individuals are affected by clinically related insomnia, in addition to almost 3 in 10 individuals who have sleep apnea.
At present solely a small share of these affected obtain the cognitive behavioral remedy for insomnia (CBT-I) advisable in Germany’s S3 guideline, in line with ResMed.
ResMed gives out-of-hospital software program applications to help folks with sleep apnea, COPD and different power ailments.
In June, ResMed signed a definitive settlement to amass Medifox Dan, a German out-of-hospital software program firm, from software program investor Hg for $1 billion (€950 million).
ON THE RECORD
Katrin Pucknat, president at ResMed Germany, stated, “The founders have recognized a big and uncared for space of wholesome sleep with a chance to assist hundreds of thousands of individuals resolve their power sleep subject with an easy-to-use digital at-home answer. We stay up for working with the crew at mementor to assist much more folks in Germany obtain good, wholesome sleep.”
E-mail the author: SMorse@himss.org